Last reviewed · How we verify
RSN0402 Part 1
RSN0402 Part 1 is a Small molecule drug developed by Shenzhen Resproly Biopharmaceutical Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | RSN0402 Part 1 |
|---|---|
| Sponsor | Shenzhen Resproly Biopharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSN0402 Part 1 CI brief — competitive landscape report
- RSN0402 Part 1 updates RSS · CI watch RSS
- Shenzhen Resproly Biopharmaceutical Co., Ltd portfolio CI
Frequently asked questions about RSN0402 Part 1
What is RSN0402 Part 1?
RSN0402 Part 1 is a Small molecule drug developed by Shenzhen Resproly Biopharmaceutical Co., Ltd.
Who makes RSN0402 Part 1?
RSN0402 Part 1 is developed by Shenzhen Resproly Biopharmaceutical Co., Ltd (see full Shenzhen Resproly Biopharmaceutical Co., Ltd pipeline at /company/shenzhen-resproly-biopharmaceutical-co-ltd).
What development phase is RSN0402 Part 1 in?
RSN0402 Part 1 is in Phase 1.
Related
- Manufacturer: Shenzhen Resproly Biopharmaceutical Co., Ltd — full pipeline
- Compare: RSN0402 Part 1 vs similar drugs
- Pricing: RSN0402 Part 1 cost, discount & access